Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia

NCT01056510 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01056510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01056510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2010
Completion date
March 31, 2014
Enrollment
357 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia, chronic